Compare Delta Air Lines, Inc. (DAL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs BIO-TECHNE Corp — how do they compare? Delta Air Lines, Inc. trades at $82.4 (market cap $54.56B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Delta Air Lines, Inc. is far larger — about 4.8× BIO-TECHNE Corp's market cap, and Delta Air Lines, Inc. pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and BIO-TECHNE Corp for 63 Days on average.
| DAL | TECH | |
|---|---|---|
Market Cap | $54.56B | $11.37B |
Volume | 6,532,736 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $93.66 | $72.61 |
52-Week Low | $55.65 | $43.31 |
Typical Hold Time | 97 Days | 63 Days |
Enterprise Value | $69.88B | $11.40B |
Dividend Yield | 1.04% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.14, down 1.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. DAL maintains solid profitability with 5.78% net margin and 20.12% ROE, while trading at attractive valuations with P/E of 13.76 and P/S of 0.8. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's internet service over Starlink.
DAL presents a compelling value opportunity with strong analyst support (82% buy ratings) and 26% upside to consensus target of $103.36. However, near-term risks include fuel cost volatility, competitive threats to premium customers, and execution challenges. The improving cash flow trend with $1.08B net cash generation in 2025 supports dividend sustainability and operational flexibility.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
